Form 4: Doximity Director Kira Scherer Wampler Executes Stock Option and Sells Shares Under 10b5-1 Plan

Kira Scherer Wampler, a director at Doximity, Inc., exercised stock options and sold 2,500 shares of Class A Common Stock at $36.27 per share, according to a recent SEC Form 4 filing.

Summary

• On September 3, 2024, Kira Scherer Wampler, a director of Doximity, Inc., executed a transaction involving the company's stock.
• Wampler exercised a stock option to acquire 2,500 shares of Class A Common Stock at an exercise price of $1.54.
• Simultaneously, Wampler sold 2,500 shares of Class A Common Stock at a price of $36.27 per share.
• These sales were executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on August 24, 2023.
• Following these transactions, Wampler directly owns 16,618 shares of Class A Common Stock and 494,700 shares of Class B Common Stock.
• The Class B Common Stock is convertible into Class A Common Stock under certain conditions, including sale, transfer, death, incapacity, or a final conversion date.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There is no indication of positive or negative implications for the company.

Future Outlook

The filing does not contain specific forward-looking statements regarding the company's future performance or outlook. The Rule 10b5-1 plan indicates pre-arranged sales, but the timing and amount of future transactions are not detailed.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company directors and officers, which is important for investors to assess management's alignment with shareholder interests. The use of a 10b5-1 plan is a common practice to avoid accusations of insider trading.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Rule 10b5-1 trading plans are widely used by executives at companies like Teladoc, Veeva Systems, and Cerner to manage their stock sales in compliance with insider trading laws.
• The reported transactions are similar to those seen in other healthcare technology companies, where executives periodically exercise stock options and sell shares for personal financial management.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by increasing the supply of shares available in the market.
• The impact on employees, customers, suppliers, and creditors is likely negligible.

Key Dates